Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 24-Feb-2022 14:12:12. This version was issued on 24-Feb-2022 14:12:12

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive

Action category: Action

Title: Antivirals and neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients

Broadcast content:

***24 February 2022: We have updated the document 'Antivirals and neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients CEM_CMO_2022_0005 to correct a link***

This policy has been updated to reflect the withdrawal of the casirivimab and imdevimab (Ronapreve) neutralising monoclonal antibody (nMAB) combination as a treatment option for patients hospitalised due to symptoms of COVID-19. This withdrawal is in the context of the dominance in the UK population of the Omicron variant of SARS-CoV-2, against which the casirivimab and imdevimab nMAB combination is ineffective.  Patients in this cohort may instead be considered for entry into the
RECOVERY trial, which is studying sotrovimab versus standard of care. Genotyping of all inpatients continues to be encouraged for surveillance purposes, but is no longer needed to confirm eligibility for any of the current COVID treatment options.   The published policy now focusses solely on patients with hospital onset COVID infection (additional criteria apply), for whom nirmatrelvir plus ritonavir (Paxlovid) is now available as a first-line treatment option.  The intravenous antiviral remdesivir (Veklury) and the monoclonal antibody sotrovimab (Xevudy) remain available as alternative treatment options in this cohort.    

Additional information: This alert does not need to be cascaded to Primary Care.

Alert reference: CEM/CMO/2022/005


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency